ES2193158T3 - Compuestos tetraciclicos agonistas de la dopamina. - Google Patents

Compuestos tetraciclicos agonistas de la dopamina.

Info

Publication number
ES2193158T3
ES2193158T3 ES94912799T ES94912799T ES2193158T3 ES 2193158 T3 ES2193158 T3 ES 2193158T3 ES 94912799 T ES94912799 T ES 94912799T ES 94912799 T ES94912799 T ES 94912799T ES 2193158 T3 ES2193158 T3 ES 2193158T3
Authority
ES
Spain
Prior art keywords
sup
tetraciclic
dopamine
compounds
agopist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94912799T
Other languages
English (en)
Inventor
Michael R Michaelides
Yufeng Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2193158T3 publication Critical patent/ES2193158T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN COMPUESTO TETRACICLICO DE FORMULA (I), DONDE A Y LOS ATOMOS A LOS CUALES ESTA UNIDA Y EL DOBLE ENLACE OPCIONAL, REPRESENTAN UN ANILLO MONO. O DI-HETEROCICLICO SELECCIONADO DE LAS FORMULAS (A), (B), (C), (D) Y (E), DONDE R{SUP.1}, R{SUP.2}, R{SUP.3}, R{SUP.4} Y X ESTAN ESPECIFICAMENTE DEFINIDOS, CUYOS COMPUESOS SON UTILES EN EL TRATAMIENTO DE DESORDENES CARDIOVASCULARES, PSICOLOGICOS Y NEUROLOGICOS RELACIONADOS CON LA DOPAMINA, ASI COMO EN EL TRATAMIENTO DE SUSTANCIAS ABUSIVAS Y OTROS COMPORTAMIENTOS DE ADICCION, PROBLEMAS COGNITIVOS Y DE ATENCION.
ES94912799T 1993-04-06 1994-03-18 Compuestos tetraciclicos agonistas de la dopamina. Expired - Lifetime ES2193158T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4342493A 1993-04-06 1993-04-06
US20998294A 1994-03-17 1994-03-17

Publications (1)

Publication Number Publication Date
ES2193158T3 true ES2193158T3 (es) 2003-11-01

Family

ID=26720416

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94912799T Expired - Lifetime ES2193158T3 (es) 1993-04-06 1994-03-18 Compuestos tetraciclicos agonistas de la dopamina.

Country Status (15)

Country Link
US (1) US5597832A (es)
EP (1) EP0690863B1 (es)
JP (1) JP2710695B2 (es)
KR (1) KR100383342B1 (es)
CN (1) CN1046723C (es)
AT (1) ATE233765T1 (es)
AU (1) AU677842B2 (es)
BR (1) BR9405972A (es)
DE (1) DE69432217T2 (es)
DK (1) DK0690863T3 (es)
ES (1) ES2193158T3 (es)
FI (1) FI954738L (es)
NO (1) NO311762B1 (es)
PT (1) PT690863E (es)
WO (1) WO1994022858A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659037A (en) * 1994-08-18 1997-08-19 Abbott Laboratories Process for preparing chiral tetracyclic dopaminergic compounds
JP3036847B2 (ja) 1995-01-13 2000-04-24 サマーセット・ファーマシューティカルズ・インコーポレイテッド デスメチルセレギリンを用いる方法および医薬組成物
WO1996025411A1 (en) 1995-02-15 1996-08-22 Neurogen Corporation Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
US5668141A (en) * 1996-04-02 1997-09-16 Abbott Laboratories Trans-2,6-,3,6-and 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzo[c]phenanthrene compounds as dopamine agonists
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
US6193954B1 (en) 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
AU750808B2 (en) 1997-10-03 2002-07-25 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
GB9828861D0 (en) * 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
US5969159A (en) * 1999-02-16 1999-10-19 Great Lakes Chemical Corporation Synthesis of cyclopentyl 2-thienyl ketone tiletamine and tiletamine acid addition salts such as tiletamine hydrochloride
US6147226A (en) * 1999-02-16 2000-11-14 Great Lakes Chemical Corporation Synthesis of cyclopentyl 2-thienyl ketone, tiletamine and tiletamine acid addition salts, such as tiletamine hydrochloride
US6638929B2 (en) * 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
AU2001283393B2 (en) * 2000-08-16 2005-09-22 Pharmacia & Upjohn Company Compounds for the treatment of addictive disorders
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
AU2003217430B2 (en) * 2002-02-15 2008-10-23 Darpharma, Inc. Mono-ester and asymmetrically substituted Di-ester pro-drugs of the dopamine D1 receptor agonists
WO2004103262A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
WO2005055920A2 (en) * 2003-12-09 2005-06-23 Yeda Research And Development Co. Ltd. Compositions and methods for treatment of psychiatric disorders
CN1964713A (zh) * 2003-12-23 2007-05-16 达法尔摩公司 多巴胺－受体结合化合物的共同使用
EP2010541A2 (en) * 2006-02-21 2009-01-07 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use
WO2010124005A1 (en) 2009-04-21 2010-10-28 Purdue Research Foundation Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
US9567316B2 (en) 2012-03-07 2017-02-14 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
CN103387583B (zh) * 2012-05-09 2018-04-13 中国科学院上海药物研究所 二芳基并[a,g]喹嗪类化合物、其制备方法、药物组合物及其应用
RU2537170C1 (ru) * 2013-11-20 2014-12-27 Войсковая Часть 41598 Средство профилактики церебральной формы острой лучевой болезни
WO2026043936A1 (en) * 2024-08-20 2026-02-26 Universidad Del Desarrollo Cysteine-bound short-chain fatty acid derivatives for the treatment of addictions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2691024A (en) * 1952-05-26 1954-10-05 Schenley Ind Inc Dihydropyrrolo-(3.2-c) quinoline derivatives
US3541100A (en) * 1967-12-14 1970-11-17 American Cyanamid Co Benzheteroazolo(2,3-a)isoquinolium salts
GB1379387A (en) * 1970-12-11 1975-01-02 Agfa Gevaert Photoconductive recording materials
US3943137A (en) * 1973-07-09 1976-03-09 University Of Kansas Endowment Association Acronycine derivatives
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
US4282227A (en) * 1980-05-22 1981-08-04 Smithkline Corporation Renal vasodilating 3,4-dihydroxyphenyltetrahydrothienopyridines
US4340600A (en) * 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
DE69334206D1 (de) * 1992-05-26 2008-04-03 Purdue Research Foundation Substituierte hexahydrobenzo(a) phenanthridine

Also Published As

Publication number Publication date
CN1124489A (zh) 1996-06-12
BR9405972A (pt) 1995-12-12
AU677842B2 (en) 1997-05-08
JP2710695B2 (ja) 1998-02-10
DE69432217D1 (de) 2003-04-10
NO953957L (no) 1995-11-21
EP0690863B1 (en) 2003-03-05
NO953957D0 (no) 1995-10-05
FI954738A7 (fi) 1995-12-05
WO1994022858A1 (en) 1994-10-13
ATE233765T1 (de) 2003-03-15
CN1046723C (zh) 1999-11-24
FI954738L (fi) 1995-12-05
EP0690863A4 (en) 1995-11-07
JPH08508487A (ja) 1996-09-10
KR100383342B1 (ko) 2003-08-25
DE69432217T2 (de) 2004-04-08
PT690863E (pt) 2003-07-31
KR960701870A (ko) 1996-03-28
AU6520394A (en) 1994-10-24
EP0690863A1 (en) 1996-01-10
DK0690863T3 (da) 2003-06-30
US5597832A (en) 1997-01-28
NO311762B1 (no) 2002-01-21
FI954738A0 (fi) 1995-10-05

Similar Documents

Publication Publication Date Title
ES2190430T3 (es) Nuevas sulfonamidas.
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
MX9203018A (es) Fluoroalcoxibencilamino-derivados de heterociclos nitrogenados.
ES2168254T3 (es) Nuevas 7-sustituidas-9-(amino sustituido)-6-desmetil-6-desoxitetraciclinas.
ES2164072T3 (es) Heterociclos no aromaticos que contienen nitrogeno sustituidos con bencilamino.
FR2387938A1 (fr) Fluorures o-carbonyles a-carboxyles fluores et leur preparation
MX9102822A (es) Variedad de planta de la fresa psi-s86.118
DK0690863T3 (da) Tetracykliske forbindelser som dopamin-agonister
ES2158327T3 (es) Derivados de benzo(g)quinolina.
ES2081005T3 (es) 9-amino-7-sustituido-6-demetil-6-deoxitetraciclinas.
ES2179945T3 (es) Compuestos de tetralina con actividad de resistencia a multiples farmacos.
ES2169150T3 (es) Compuestos a base de dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
ES2107035T3 (es) Derivados de 3-azabiciclo(3.2.0)heptano n-substituidos como neurolepticos etc..
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
ES2059416T3 (es) 1,4-dihidropiridina-enantiomeros.
ES2110260T3 (es) Androstenonas.
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
ES2101073T3 (es) Nuevos aza-androstano-derivados 17-beta-substituidos.
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
ES2153019T3 (es) Derivados de benzo-dioxano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES462103A1 (es) Procedimiento para la preparacion del derivado yodurado de cloruro de benzalconio.
ES2174156T3 (es) Perinonas, quinoftalonas y perinona-quinoftalonas puenteadas.
AR004664A1 (es) Compuestos de dihalopropeno, insecticidas que los contienen como ingredientes activos, y compuestos intermedios para su produccion
ES2173195T3 (es) Derivados de antraciclina.
ES2029799T3 (es) Derivados de 2,5,6,7 tetranor-4,8-inter-m-fenilen pg12.